Discounted Cash Flow
Arcus Biosciences, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-18.0m | $-17.0m | — | — |
| 2017 | $1.4m | $-53.1m (-195.4%) | $-30.6m (-79.4%) | -3756.7% | — |
| 2018 | $8.4m (491.2%) | $-49.6m (6.6%) | $-46.7m (-52.9%) | -593.7% (84.2%) | — |
| 2019 | $15.0m (79.6%) | $-84.7m (-70.8%) | $-75.4m (-61.3%) | -564.7% (4.9%) | — |
| 2020 | $77.5m (416.8%) | $-122.9m (-45.0%) | $108.1m (243.4%) | -158.5% (71.9%) | — |
| 2021 | $382.9m (393.9%) | $52.8m (143.0%) | $-282.2m (-361.1%) | 13.8% (108.7%) | $0.76 |
| 2022 | $112.0m (-70.7%) | $-267.0m (-605.4%) | $432.0m (253.1%) | -238.4% (-1827.7%) | $-3.71 (-588.2%) |
| 2023 | $117.0m (4.5%) | $-307.0m (-15.0%) | $-330.0m (-176.4%) | -262.4% (-10.1%) | $-4.15 (-11.9%) |
| 2024 | $51.0m (-56.4%) | $-283.0m (7.8%) | $-176.0m (46.7%) | -554.9% (-111.5%) | $-3.14 (24.3%) |
| 2025 | $33.0m (-35.3%) | $-353.0m (-24.7%) | $-484.0m (-175.0%) | -1069.7% (-92.8%) | $-3.29 (-4.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.